Data from Marshall Pearce - Curated by EPG Health - Last updated 03 April 2017

About Marshall Pearce

Dr Marshall Pearce joined EPG Health Media in May 2016, having practised as doctor for 7 years. Marshall embarked on GP training before becoming a medical writer, he studied at Brighton Sussex Medical School. 

Outside of work, Marshall enjoys exploring the Kent and Sussex countryside with his two (somewhat) unruly dogs, playing tennis, and reading fiction and non-fiction novels of varying quality.


Horizons articles by Marshall Pearce

Left ventricular assist devices – A viable therapeutic option for heart failure?

Alongside a pharmacological strategy to aid myocardial recovery, LVADs may prove to have a significant role to play in the ever-growing problem of heart failure. Although LVADs are not new onto the scene, the advance of technology – smaller, more efficient devices with better reliability and potentially transcutaneous power transfer – means we may be on the cusp of seeing many more deployed to tackle heart failure.

Posted 2 years ago

Antibody-drug conjugates (ADCs)

Over the past couple of decades, there have been advances in a class of drugs which for a long time was purely theoretical: antibody-drug conjugates (ADCs). The concept underlying ADCs is elegant – what if it were possible to ‘target’ particular groups of cells with a cytotoxic agent, rather than exposing every cell of the body to it?

Posted 2 years ago

Cancer immunotherapies

It was the winner of the 1908 Nobel prize for medicine, Paul Ehrlich, who is first credited with discussing the concept of a “magic bullet”, able to target specific cells without damaging healthy tissue. With the advent of immunotherapy, as well as antibody-drug conjugates, we are beginning to realise this vision.

Posted 2 years ago

How close are we to a disease-modifying treatment for Alzheimer’s?

Alzheimer’s disease is a snowballing problem, one that is currently without a convincing solution. The progressive decline in cognitive function seen in patients with Alzheimer’s disease is associated strongly with plaques formed of amyloid beta in the brain, creating neurofibrillary tangles and leading to neuronal destruction. While some treatments improve cognition in the short-term, current therapeutic options are unable to modify or slow the disease process.

Posted 1 year ago